The FDA has issued the first-ever emergency use authorization (EUA) for a drug to combat New World screwworm myiasis in dogs, according to the American Veterinary Medical Association (AVMA). The authorization marks the first time the agency has used this emergency mechanism for a screwworm product in any U.S. animal population.

The decision gives veterinarians a legally permitted therapeutic option against a parasite that has been advancing northward through the Americas and has no routinely approved canine treatment on the U.S. market.

Why an emergency use authorization?

An EUA permits the FDA's Center for Veterinary Medicine (FDA CVM) to allow use of an unapproved product during a declared emergency, when no adequate approved alternative exists. This is the framework the agency reserves for emerging threats rather than the standard new animal drug approval pathway, which typically requires multi-year efficacy and safety data packages.

For practicing veterinarians, the practical effect is immediate: the authorized drug may now be used in dogs under the conditions the FDA has specified, before a full approval is in place. Clinicians should consult the authorization's terms directly, as EUAs define permitted patient populations, dosing parameters, and reporting requirements.

What does this change at the exam table?

Screwworm myiasis occurs when Cochliomyia hominivorax larvae infest open wounds and feed on living tissue, rather than dead tissue as most other fly larvae do. Dogs with untreated wounds, surgical sites, or tick bites are among the domestic species at risk when the fly is present in a region.

The companion-animal implications come first for most readers of this authorization. A confirmed or suspected case in a dog previously left veterinarians without a cleared pharmaceutical option, forcing off-label improvisation. The EUA closes that gap for the duration of the emergency.

Food-animal and public-health dimensions remain significant. Screwworm infests cattle and other livestock, and the parasite's larvae can infest humans as well. The United States eradicated the fly decades ago through the sterile insect technique, and the USDA maintains a permanent quarantine barrier in Panama. Any U.S. animal case therefore carries regulatory consequences beyond the individual patient.

What should veterinarians do now?

The AVMA's report directs practitioners to the FDA's authorization documentation for the drug's exact conditions of use. Key operational points for clinics:

• Verify the authorization's scope before administration, including any restrictions on patient signalment or clinical presentation.
• Report suspected screwworm cases to state and federal veterinary authorities, as the parasite is a reportable pest.
• Apply the product only within the EUA's permitted use conditions, since emergency authorizations do not equal full approval.

Veterinarians in southern border states face the most direct relevance, given the parasite's established presence in parts of Central America and its documented northward movement in recent years.

How unusual is this action?

Emergency use authorizations in veterinary medicine are rare. The FDA CVM used the mechanism sparingly even during recent high-consequence animal health events. A first-ever EUA for a screwworm drug in dogs signals that regulators judge the current risk level — and the absence of approved alternatives — serious enough to justify emergency tools.

For a frame of reference: full new animal drug approvals routinely take years of review, while an EUA can be issued within weeks once an emergency determination stands. That speed is the entire point of the mechanism.

What comes next?

The authorization remains in effect for the period the FDA specifies and can be revised or revoked as the epidemiological picture changes. Whether the drug proceeds toward full approval will depend on data generated during this emergency use period. Veterinarians treating dogs in affected regions should monitor FDA CVM and AVMA communications for updates on the authorization's status and any expansion of its permitted use.